STAT+: Supreme Court rules against Amgen in closely watched case over scope...
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld a lower court ruling that Amgen failed to disclose sufficient information about patent claims for a best-selling...
View ArticleSTAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep...
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company...
View ArticleSTAT+: Pharmalittle: PBMs are targeted in yet another congressional bill;...
Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus...
View ArticleSTAT+: Pharmalittle: Eisai executive to retire; Express Scripts adds three...
Top of the morning to you, and a fine one it is. Birds are chirping and cool breezes are wafting by the Pharmalot campus, where the official mascots are racing about the grounds. As for us, we are...
View ArticleSTAT+: STAT Virtual Event: The State of Biosimilars: What to Watch
Editor’s note: A recording of the event is embedded below. Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can...
View ArticleOpinion: STAT+: The problem with potential changes to the biosimilar...
Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation...
View ArticleOpinion: STAT+: A year in, the U.S. is still not taking advantage of...
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved...
View ArticleOpinion: STAT readers on what human health care can learn from veterinary...
STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here, or...
View ArticleSTAT+: Here’s what you might have missed in Biden’s budget proposal
WASHINGTON — President Biden on Monday unveiled his requests for the 2025 budget, potentially his last chance to cement a legacy on drug costs, cancer research, and broad health care coverage. The...
View ArticleClik here to view.
STAT+: Virtual Event: March of the Biosimilars
Editor’s note: A recording of the event is embedded below. Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year....
View ArticleSTAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira...
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive...
View ArticleSTAT+: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing...
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first...
View ArticleOpinion: PBMs aren’t opening access to lower-cost biosimilars. Reform is...
The Federal Trade Commission presents on Thursday its interim staff report, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies.” It reveals how...
View ArticleOpinion: Improving the FDA-EMA parallel scientific advice program to advance...
Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics...
View ArticleSTAT+: J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one manufacturer of striking a “surreptitious” deal that could arguably...
View ArticleSTAT+: More Medicare plans cover Humira biosimilars, but do little to...
Medicare drug plans significantly boosted coverage of biosimilar versions of the Humira rheumatoid arthritis medicine this year, but nearly all of them failed to take steps that would encourage greater...
View ArticleSTAT+: How Regeneron, maker of a best-selling eye drug, is using patent...
A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents to thwart competition. And...
View ArticleSTAT+: FDA moves to ease path for biosimilars as Trump seeks to cut drug costs
WASHINGTON — The Trump administration announced a draft framework Wednesday that officials say will speed cheaper versions of biologic drugs to market with the aim of making medicine more affordable...
View ArticleHow Mark Cuban plans to ‘f— up’ health care
How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible...
View ArticleOpinion: STAT+: Sandoz chief scientific officer: What is truly necessary to...
Every day, I think about the patients waiting for medicines that could change, or even save, their lives. For them, access is not a statistic. It is hope, health, and a chance for a better future....
View Article
